Literature DB >> 22676150

Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: a decision analysis.

M I Rodriguez1, M F Reeves, A B Caughey.   

Abstract

OBJECTIVE: To model the risk of HIV acquisition and maternal mortality for women in four African countries in the light of previous data on risk of HIV acquisition and hormonal contraceptive use.
DESIGN: Decision analysis.
SETTING: Chad, Kenya, South Africa and Uganda. POPULATION: Women of reproductive age, at risk of HIV, who do not desire pregnancy.
METHODS: A decision analysis model was built to compare the consequences of removing progestin injectables from use, assuming an increased risk of HIV acquisition. Three scenarios were considered in four African countries: replacement of progestin injectables with no method, with combined oral contraceptives (COC) or with an intrauterine device (IUD). Health outcomes measured include: life-years, maternal mortality, HIV acquisition and unsafe abortion. Sensitivity analysis, including Monte Carlo simulation, was performed around all variables. MAIN OUTCOME MEASURES: HIV acquisition, maternal mortality and life-years.
RESULTS: If progestin injectables are removed from use, without a minimum of 70-100% of women switching to an IUD or COCs, up to nine additional maternal deaths will occur for every case of HIV averted. Sensitivity analysis demonstrated that this finding persisted across a broad range of variables.
CONCLUSIONS: Contraception is critical to preserving life for women in Africa. In the absence of clear evidence regarding hormonal contraception and HIV acquisition, policy decisions must not overlook the very real risk of maternal mortality.
© 2012 World Health Organization BJOG An International Journal of Obstetrics and Gynaecology © 2012 RCOG.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22676150     DOI: 10.1111/j.1471-0528.2012.03402.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  17 in total

Review 1.  Hormonal Contraception and HIV-1 Acquisition: Biological Mechanisms.

Authors:  Janet P Hapgood; Charu Kaushic; Zdenek Hel
Journal:  Endocr Rev       Date:  2018-02-01       Impact factor: 19.871

2.  Maximizing the impact of HIV prevention efforts: interventions for couples.

Authors:  Amy Medley; Rachel Baggaley; Pamela Bachanas; Myron Cohen; Nathan Shaffer; Ying-Ru Lo
Journal:  AIDS Care       Date:  2013-05-08

3.  Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs.

Authors:  Richard P H Huijbregts; Katherine G Michel; Zdenek Hel
Journal:  Contraception       Date:  2014-02-26       Impact factor: 3.375

4.  A prospective cohort study of the effect of depot medroxyprogesterone acetate on detection of plasma and cervical HIV-1 in women initiating and continuing antiretroviral therapy.

Authors:  Summer Day; Susan M Graham; Linnet N Masese; Barbra A Richardson; James N Kiarie; Walter Jaoko; Kishorchandra Mandaliya; Vrasha Chohan; Julie Overbaugh; R Scott McClelland
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-01       Impact factor: 3.731

Review 5.  Contraceptive methods and risk of HIV acquisition or female-to-male transmission.

Authors:  Lisa B Haddad; Chelsea B Polis; Anandi N Sheth; Jennifer Brown; Athena P Kourtis; Caroline King; Rana Chakraborty; Igho Ofotokun
Journal:  Curr HIV/AIDS Rep       Date:  2014-12       Impact factor: 5.071

6.  Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies.

Authors:  Lauren J Ralph; Sandra I McCoy; Karen Shiu; Nancy S Padian
Journal:  Lancet Infect Dis       Date:  2015-01-09       Impact factor: 25.071

7.  Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract.

Authors:  Katherine G Michel; Richard P H Huijbregts; Jonathan L Gleason; Holly E Richter; Zdenek Hel
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

8.  Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.

Authors:  Lisa M Noguchi; Barbra A Richardson; Jared M Baeten; Sharon L Hillier; Jennifer E Balkus; Z Mike Chirenje; Katherine Bunge; Gita Ramjee; Gonasagrie Nair; Thesla Palanee-Phillips; Pearl Selepe; Ariane van der Straten; Urvi M Parikh; Kailazarid Gomez; Jeanna M Piper; D Heather Watts; Jeanne M Marrazzo
Journal:  Lancet HIV       Date:  2015-07       Impact factor: 12.767

9.  Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms.

Authors:  Richard P H Huijbregts; E Scott Helton; Katherine G Michel; Steffanie Sabbaj; Holly E Richter; Paul A Goepfert; Zdenek Hel
Journal:  Endocrinology       Date:  2013-01-25       Impact factor: 4.736

10.  Medical eligibility, contraceptive choice, and intrauterine device acceptance among HIV-infected women receiving antiretroviral therapy in Lilongwe, Malawi.

Authors:  Lisa B Haddad; Caryl Feldacker; Denise J Jamieson; Hannock Tweya; Carrie Cwiak; Amy G Bryant; Mina C Hosseinipour; Thomas Chaweza; Linly Mlundira; Fanny Kachale; Gretchen S Stuart; Irving Hoffman; Sam Phiri
Journal:  Int J Gynaecol Obstet       Date:  2014-05-13       Impact factor: 3.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.